Traditional chemotherapy used today at clinics is mainly inherited from the thinking and
designs made four decades ago when the Cancer War was declared. The potency of those …

Nanomedicines generally consisting of carrier materials with small fractions of active
pharmaceutical ingredients (API) have long been used to improve the pharmacokinetics and …

Nanomedicine as a field has emerged from the early success of nanoparticle-based drug
delivery systems, in particular for treatment of cancer, and the advances made in nano-and …

Phospholipase A2 (PLA2) enzymes (EC3. 1.4. 4) regulate the release of biologically active
fatty acids and lysophospholipids from membrane phospholipid pools. These lipids are also …

Background Breast cancer is very common and highly fatal in women. Current non-invasive
detection methods like mammograms are unsatisfactory. Lipidomics, a promising detection …

Phospholipase A2 (PLA2) are esterases that cleave glycerophospholipids to release fatty
acids and lysophospholipids. Inhibition of PLA2 alters cancer cell growth and death in vitro …

Breast cancer accounts for the largest number of newly diagnosed cases in female cancer
patients. Although mammography is a powerful screening tool, about 20% of breast cancer …

Highly effective delivery of therapeutic agents into target cells using nanocarriers and
subsequently rapid intracellular release are of great importance in cancer treatment. Here …

Purpose: Arachidonate release contributes to prostate tumor progression as arachidonate is
metabolized into prostaglandins and leukotrienes, potent mediators of immune suppression …

Malignant human breast tumours contain high levels of prostaglandin E2 (PGE2). However,
the mechanisms controlling PGE2 production in breast cancer are unknown. This in vitro …